11 completed, 1 unknown. 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 11, Unknown 1 |
Follow zopiclone: new trials by email Literature Review of zopiclone trials Research Report on zopiclone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women Elinzanetant (BAY3427080), Placebo to elinzanetant, Zopiclone - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes | Phase 1 | Completed | Bayer | 64 | 2024-01-08 | 2024-05-08 |
| A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects TS-142, Zopiclone, Placebo - Healthy Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 43 | 2023-05-15 | 2025-02-28 |
| A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects TS-142, Zopiclone, Placebo - Healthy Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 61 | 2021-01-16 | 2025-02-28 |
| A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder Seltorexant Dose 1, Seltorexant Dose 2, Placebo - Depressive Disorder, Major | Phase 1 | Completed | Janssen Research & Development, LLC | 63 | 2020-07-16 | 2025-04-27 |
| A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects ACT-541468, Zopiclone 7.5 mg, Placebo - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 56 | 2019-03-25 | 2019-10-31 |
| Hangover and Residual Zopiclone Effect on Spatial Perception Zopiclone, hangover, Placebo oral capsule - Healthy, Alcohol Drinking | Phase 1 | Unknown | Petri Vainio | 16 | 2018-09-01 | 2018-08-15 |
| Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects Placebo tablet matching lemborexant, Placebo tablet matching zopiclone, Zopiclone 7.5 mg - Healthy Participants | Phase 1 | Completed | Eisai Inc. | 48 | 2015-11-01 | 2018-09-06 |
| MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers Jelly with:Paracetamol, Jelly with Furosemide, Jelly with Levothyroxine sodium salt - Healthy | Phase 1 | Completed | Centre Hospitalier Universitaire de Nice | 16 | 2014-06-01 | 2015-10-07 |
| A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1) MK-4305 40 mg, MK-4305 20 mg, Zopiclone - Insomnia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 28 | 2011-04-01 | 2016-02-22 |
| Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet zopiclone, zolpidem tartrate sublingual tablet, Placebo (sublingual tablet) - Insomnia | Phase 1 | Completed | Transcept Pharmaceuticals | 40 | 2010-06-01 | 2012-02-14 |
| A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED) Org 50081, Placebo, zopiclone - Sleep Initiation and Maintenance Disorders, Mental Disorders | Phase 1 | Completed | Merck Sharp & Dohme LLC | 32 | 2007-10-01 | 2015-10-14 |
| Effects of Ramelteon on Driving Ability Ramelteon 8 mg, Zopiclone 7.5 mg - Insomnia | Phase 1 | Completed | Utrecht Institute for Pharmaceutical Sciences | 30 | 2006-03-01 | 2007-04-25 |
Sleep Initiation and Maintenance Disorders (4) · Alcohol Drinking (1) · Depressive Disorder, Major (1) · Hot Flashes (1) · Mental Disorders (1) · Multiple Endocrine Neoplasia Type 1 (1)
Merck Sharp & Dohme LLC (2) · Taisho Pharmaceutical Co., Ltd. (2) · Bayer (1) · Centre Hospitalier Universitaire de Nice (1) · Eisai Inc. (1) · Idorsia Pharmaceuticals Ltd. (1) · Janssen Research & Development, LLC (1) · Petri Vainio (1) · Transcept Pharmaceuticals (1) · Utrecht Institute for Pharmaceutical Sciences (1)
Netherlands (5) · Japan (2) · Belgium (1) · Canada (1) · Finland (1) · France (1) · Germany (1)
Annemiek Vermeeren, PhD (1) · Joris Verster, PhD (1) · Petri J Vainio, MD (1)
PMID 21966064, PMID 24587571, PMID 30597112, PMID 39120786, PMID 40569207, PMID 42174196
2019 (1)